These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24094513)

  • 1. Neuroimaging biomarkers for early drug development in schizophrenia.
    Tregellas JR
    Biol Psychiatry; 2014 Jul; 76(2):111-9. PubMed ID: 24094513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimaging Biomarkers in Schizophrenia.
    Kraguljac NV; McDonald WM; Widge AS; Rodriguez CI; Tohen M; Nemeroff CB
    Am J Psychiatry; 2021 Jun; 178(6):509-521. PubMed ID: 33397140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.
    Gandal MJ; Edgar JC; Klook K; Siegel SJ
    Neuropharmacology; 2012 Mar; 62(3):1504-18. PubMed ID: 21349276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication.
    Hutcheson NL; Sreenivasan KR; Deshpande G; Reid MA; Hadley J; White DM; Ver Hoef L; Lahti AC
    Hum Brain Mapp; 2015 Apr; 36(4):1442-57. PubMed ID: 25504918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological biomarkers for drug development in schizophrenia.
    Javitt DC; Spencer KM; Thaker GK; Winterer G; Hajós M
    Nat Rev Drug Discov; 2008 Jan; 7(1):68-83. PubMed ID: 18064038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive impairment in schizophrenia and how it affects treatment options.
    Bilder RM
    Can J Psychiatry; 1997 Apr; 42(3):255-64. PubMed ID: 9114941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
    Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications.
    Green MF; Braff DL
    Biol Psychiatry; 2001 Feb; 49(4):374-84. PubMed ID: 11239909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.
    Heckers S; Konradi C
    Schizophr Res; 2015 Sep; 167(1-3):4-11. PubMed ID: 25449711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional neuroimaging in treatment resistant schizophrenia: A systematic review.
    Molent C; Olivo D; Wolf RC; Balestrieri M; Sambataro F
    Neurosci Biobehav Rev; 2019 Sep; 104():178-190. PubMed ID: 31276716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of resting state gamma power as a response marker in schizophrenia.
    Mitra S; Nizamie SH; Goyal N; Tikka SK
    Psychiatry Clin Neurosci; 2015 Oct; 69(10):630-9. PubMed ID: 25854748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia.
    Bartholomeusz CF; Ganella EP; Labuschagne I; Bousman C; Pantelis C
    Schizophr Res; 2015 Nov; 168(3):614-27. PubMed ID: 26123171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EEG-Informed fMRI Reveals a Disturbed Gamma-Band-Specific Network in Subjects at High Risk for Psychosis.
    Leicht G; Vauth S; Polomac N; Andreou C; Rauh J; Mußmann M; Karow A; Mulert C
    Schizophr Bull; 2016 Jan; 42(1):239-49. PubMed ID: 26163477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.
    Wilson C; Terry AV
    Clin Schizophr Relat Psychoses; 2010 Jul; 4(2):124-37. PubMed ID: 20643635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurodevelopmental theories of schizophrenia--preclinical studies].
    Lehner M; Taracha E; Wisłowska A; Zienowicz M; Maciejak P; Skórzewska A; Płaźnik A
    Psychiatr Pol; 2003; 37(4):627-39. PubMed ID: 14560492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic modulation of intrinsic brain networks in schizophrenia.
    Smucny J; Tregellas J
    Biochem Pharmacol; 2013 Oct; 86(8):1163-72. PubMed ID: 23796751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sleep deprivation on inhibitory biomarkers of schizophrenia: implications for drug development.
    Ettinger U; Kumari V
    Lancet Psychiatry; 2015 Nov; 2(11):1028-35. PubMed ID: 26544751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal functional connectivity of high-frequency rhythms in drug-naïve schizophrenia.
    Takahashi T; Goto T; Nobukawa S; Tanaka Y; Kikuchi M; Higashima M; Wada Y
    Clin Neurophysiol; 2018 Jan; 129(1):222-231. PubMed ID: 29202390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.